Ovarian Committee. Closed Trials Upfront Surgery vs Neoadjuvant Chemotherapy Patients closed / 550 Leading EORTC Participating NCIC CTG Presentation. - ppt download
Efficacy | LIBRETTO-001 Trial | Retevmo® (selpercatinib) | HCP
SellZone® Assembled Desktop Computer Core 2 Duo 3.0GHZ Processor, G31 Motherboard, 17 Inch LED Monitor, 4GB RAM, Windows 7 & Office Trial Version with Web Camera Mic Speaker (Hard Drive, 250GB) :
New Data Support Debulking to Prolong Survival in Women With Platinum-Sensitive Recurrent Ovarian Cancer
A trial looking at surgery for ovarian cancer that has come back (DESKTOP 3, ENGOT ov20) | Cancer Research UK
Research Update on Ovarian Cancer | PPT
Clinical trials - Aarhus Universitetshospital
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
Shannon Westin on X: "This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 #SGOatASCO #gyncsm https://t.co/pHGWklYWKs" / X
Shannon Westin on X: "Cross trial comparisons are always tricky...but, comparing the survival curves between the trials gives great pause - the GOG213 medians are markedly higher. Many thanks to @rcoledude for
Clinical Conundrums: Choosing the Best Management Approaches in Patients With Ovarian Cancer Thomas J. Herzog, MD Director, Division of Gynecologic Oncology. - ppt download
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
RECENT ADVANCES CA OVARY.pptx
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
IV IBERICAVIP Pack Desktop III | PC de Oficina Completo (AMD Ryzen 7 5700G / 16GB / 500GB SDD/WiFi) Windows 10 Pro Trial, Monitor 27", Teclado y Ratón Inalámbricos : Amazon.es: Informática
Mauricio Lema-Medina on X: "#esmo17 -DESKTOP III: Only potential R0 resection (<500 mL ascites, Good PS, Optimal 1ry debulking) should undergo 2ry cytoreduction in OvCa https://t.co/WP7uHBw4pr" / X
IJGC on X: "#podcast: The DESKTOP III Trial with Philipp Harter This week, @pedroramirezMD is joined by Prof. Philipp Harter to discuss The DESKTOP III Trial. ♫https://t.co/CZQXdMT97W @_kem @IGCSociety @ESGO_society @OncoAlert @agz_eriksson #
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
ASCO 2020: AGO DESKTOP III Highlights Importance of Complete Resection in Recurrent Ovarian Cancer | PracticeUpdate
Shannon Westin on X: "Patient selection clearly matters - DESKTOP III used the AGO criteria, SOC-1 used iMODEL score - both have been validated to predict ability to achieve complete resection -
PPT - OVARIAN CANCER COMMITTEE Phillip Harter / Christian Marth PowerPoint Presentation - ID:3280265
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
